Guaranteed adherence.
Better outcomes.™

Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.

Addressing the biggest challenges in chronic disease treatment – medication non-adherence and tolerability.

An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.

Hear from our CEO, Dr. Adam Mendelsohn, on our revolutionary approach to challenges associated with patient behavior.

Of patients do not adhere to their medication due to forgetfulness and inertia.

Our long-term solution for life-long conditions.

At Vivani we are developing our novel NanoPortal™ implant technology for delivering the intended dose of medication steadily over extended periods of time. It has been engineered with the goal of avoiding challenges that may be associated with fluctuating drug delivery.

Our Lead Drug Candidate: NPM-119

GLP-1 Receptor Agonist

NPM-119 is a miniature, subdermal, exenatide drug implant designed to treat the growing number of patients with type 2 diabetes. This device can be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months.

Starting Soon: Our First NPM-119 Clinical Study

We are currently preparing to initiate LIBERATE-1, a First-in-Human clinical study of NPM-119 in patients with type 2 diabetes for a 12-week treatment period.

News & Updates

Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for…

 Read More  

Vivani Medical Reports Second Quarter Financial Results and Provides Business Update

 Read More  

Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The…

 Read More  

Vivani Medical to Present at the Boulder Peptide Symposium

 Read More  

Vivani Medical to Present at BIO Investor Forum

 Read More  

Vivani Medical Provides Business Update and Reports Third Quarter Financial Results

 Read More  

Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference…

 Read More  

Vivani Medical Reports First Quarter Financial Results and Provides Business Update

 Read More  

Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing…

 Read More  

Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and…

 Read More  

< >

Current Disease Targets of NanoPortal Platform Technology

Type 2 Diabetes


(Non-Alcoholic Steatohepatitis)

Pre-Diabetes & Diabetes